FORMULATION DESIGN, CHARACTERIZATION AND EVALUATION OF SUSTAINED RELEASE TABLET OF TERBUTALINE SULPHATE: A MODIFIED MATRIX TECHNOLOGY

Abstract

Introduction: The sustained release formulation is more effective than conventional release tablet in nocturnal asthma. Nocturnal asthma arises at the night time or sleeping time. The dose of terbutaline sulphate is 15 mg/day with biological half life of 3-4 hrs leads to the dosing frequency 6-8 times in a day. To overcome the issue related to attack of nocturnal asthma in night time or while sleeping, a conventional dosage form fall short to control the same. Thus the sustained release formulation, once administered, is more effective to control the probable attack of nocturnal asthma for overnight. Material and Methods: The sustained release formulation of Terbutaline sulphate (TS) is developed by modified wet granulation technique with the aid of polymers viz. Hydroxy Propyl Methyl Cellulose (HPMC K4M), Ethyl cellulose, Eudragit RS 100 and Microcrystalline cellulose (MCC). Results and Discussion: Terbutaline sulphate is a selective \beta -2 adrenoceptor agonist & widely used in nocturnal asthma. The best formulation was TS7 containing ethyl cellulose with eudragit RS 100 in context to the dissolution profile, release kinetics and drug content. The prepared sustained release matrix tablet of terbutaline sulphate IP may be used in the treatment of bronchial & night time asthma. Conclusion: The present study concludes the better results of in vitro release for 12 hrs. It follows higuchi model of release kinetics, mean the drug release from matrix.